| News
Roche and Novartis among most valuable companies
02.01.2018
The Basel pharmaceutical companies Roche and Novartis are among the 40 most valuable companies in the world, according to an EY study. American tech firms top the list.
Money. (Img: aleksandra85foto/pixabay)
The consultancy firm EY has again compared the 300 highest rated companies in the world – and once again the top 100 is dominated by US companies. Three Swiss companies were among the top 100: Nestlé ($264 billion/18th place), Roche ($213 billion/31st place) and Novartis ($195 billion/37th place).
“Although the European economy is now recovering sharply, Europe’s top companies still continue to play only a minor role on the world’s stock exchanges,” said Stefan Rösch, partner and head of transaction services at EY in Switzerland. “Although we are still well ahead with Nestlé and our two pharma companies, the opportunities offered by digitalization nonetheless need to be exploited more effectively in this country.”
Three US companies from the tech sector – Apple ($876 billion), Google’s owner Alphabet ($733 billion) and Microsoft ($661 billion) – captured the top three places. The Chinese internet giants Tencent and Alibaba, which doubled in value over the past year, also made it into the top 10. The US company Johnson & Johnson ($377 billion) was the highest ranked pharmaceutical company, coming in 10th place.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
docdok.health involved in coronavirus research project
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
Celonic agrees cooperation to combat coronavirus
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
Idorsia receives payment of 45 million US dollars
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard robot disinfects using UV light
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche authorized to distribute coronavirus antibody tests
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Read More
Healthtech sector growing rapidly in the Basel Area
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.
Read More
Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
Read More
University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Read More
Botnar Research Center advancing research into coronavirus
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
Read More
